Her2 amplification status in Iranian breast cancer patients: Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH)

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 4, 2011, Pages 1031-1034

  Ghaffari, Saeed Reza ^a,b   Sabokbar, Tayebeh ^a,b   Dastan, Jila ^b   Rafati, Maryam ^a   Moossavi, Shirin ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Gene Clinic   (Iran)

Author keywords

Breast cancer; FISH; Her2; Immunohistochemistry; Trastuzumab

Indexed keywords

EID: 84856275833     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cobleigh MA, Vogel CL, Tripathy D, et al (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639-48.
2. Couturier J, Vincent-Salomon A, Nicolas A, et al (2000). Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol, 13, 1238-43.
3. De Laurentiis M, Arpino G, Massarelli E, et al (2005). A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clinical cancer research, 11, 4741-8.
4. Dolan M, Snover D (2005). Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice. Am J Clin Pathol, 123, 766-70.
5. Dowsett M, Hanna WM, Kockx M, et al (2007). Standardization of HER2 testing: results of an international proficiencytesting ring study. Modern Pathology, 20, 584-91.
6. Dybdal N, Leiberman G, Anderson S, et al (2005). Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast cancer research and treatment, 93, 3-11.
7. Ferlay J, Shin H, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. Retrieved January 30, 2011, from http://globocan.iarc.fr
8. Harris L, Fritsche H, Mennel R, et al (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312.
9. Hynes NE, MacDonald G (2009). ErbB receptors and signaling pathways in cancer. Current opinion in cell biology, 21, 177-184.
10. Ménard S, Valagussa P, Pilotti S, et al (2001). Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node - positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol, 19, 329-35.
11. Moelans CB, Van Diest PJ, Milne ANA, et al (2011). Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathol Res Int, doi:10.4061/2011/674182
12. Owens MA, Horten BC, Da Silva MM (2004). HER2 Amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues. Clin Breast Cancer, 5, 63-9.
13. Paik S, Bryant J, Tan-chiu E, et al (2002). Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst, 94, 852-4.
14. Pauletti G, Godolphin W, Press M, et al (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene, 13, 63-72.
15. Pauletti G, Dandekar S, Rong H, et al (2000). Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol, 18, 3651-64.
16. Perez EA, Roche PC, Jenkins RB, et al (2002). HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 77, 148-54.
17. Phillips KA, Marshall DA, Haas JS, et al (2009). Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer, 115, 5166-74.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Trastuzumab after adjuvant chemotherapy in HER2-Positive Breast Cancer. NEJM, 353, 1659-72.
19. Press MF, Sauter G, Bernstein L, et al (2005). Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res, 11, 6598-607.
20. Pritchard KI, Shepherd LE, O'Malley FP, et al (2006). HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. NEJM, 354, 2103-11.
21. Roche PC, Suman VJ, Jenkins RB, et al (2002). Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst, 94, 855-7.
22. Slamon DJ, Clark GM, Wong SG, et al (1987). Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science, 235, 177-82.
23. Smith I, Procter M, Gelber RD, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36.
24. Tubbs RR, Pettay JD, Roche PC, et al (2001). Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol, 19, 2714-21.
25. Villman K, Sjöström J, Heikkilä R, et al (2006). TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta oncologica, 45, 590-6.
26. Wieduwilt MJ, Moasser MM (2008). The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci, 65, 1566-84.
27. Wolff AC, Hammond MEH, Schwartz JN, et al (2007). American Society of Clinical Oncology / College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131, 18-43.